doi: 10.4143/crt.2017.562 39. Hamanishi J, Takeshima N, Katsumata N, Ushijima K, Kimura T, Takeuchi S, et al. Nivolumab versus gemcitabine or pegylated liposomaldoxorubicin for patients with platinum-resistant ovarian cancer: Open-label, randomized trial in Japan. (NINJA) J Clin Oncol (2021) 39(33):3671 –81. doi: 10.1200/JCO.21.00334 40. Bellone G, Smirne C, Mauri FA, Tonel E, Carbone A, Buffolino A, et al. Cytokine expression pro ﬁle in human pancreatic carcinoma cells and in surgical specimens: implications for survival. Cancer Immunol Immunother (2006) 55 (6):684 –98. doi: 10.1007/s00262-005-0047-0 41. Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-Mediated inhibition in regulation of T cell responses: Mechanisms and manipulation intumor immunotherapy. Annu Rev Immunol (2001) 19(1):565 –94. doi: 10.1146/ annurev.immunol.19.1.565 COPYRIGHT © 2022 Shou, Mo, Zhang, Lu, Han, Liu, Qiu, Li, Han, Ma, Guo, Guo, Huang, Zhang, Ye, Pan, Chen and Fang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted,provided the original author(s) and the copyright owner(s) are creditedand that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.Shou et al. 10.3389/ ﬁmmu.2022.1000681 Frontiers in Immunology frontiersin.org 16